Natera Inc (NTRA) Stock Price, Quote & News

Company Profile

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provi...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 980 9190

Website: www.natera.com

Address:

13011 McCallen Pass, Building A Suite 100, Austin, United States

JUST_FACTSSS Sep. 3 at 10:39 PM

$NTRA SPRTS = 290.00 (50DMA)+272 +263 +251(100DMA) <--' BUY 🎯

0 · Reply

MaverikIT Sep. 1 at 6:16 PM

Jblack500 @WAJeff @cynicaloptimist @BustaCapital @IsabellaDC $IRTC $GH $NTRA PLSE ...

0 · Reply

peloswing Sep. 1 at 5:52 PM

Unusual Options Activity: $NTRA $1.6M+ of the $350 calls for 11/20 Also $63,000 of the $410 calls for Aug. 2027

0 · Reply

Agile_Mango_Penguin Sep. 1 at 11:56 AM

$NTRA AMP capital updated price target $500 in 2027

0 · Reply

S_Franconi Sep. 1 at 11:45 AM

$NTRA New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma https://investor.natera.com/news/news-details/2026/New-Publication-Establishes-Strong-Clinical-Validation-of-Signatera-for-MRD-Assessment-in-Lymphoma/default.aspx

0 · Reply

JFDI Aug. 30 at 7:42 PM

$NTRA druck sayzzzz dips r a ...

0 · Reply

S_Franconi Aug. 28 at 4:51 PM

$NTRA Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer https://investor.natera.com/news/news-details/2026/Natera-and-Susan-G--Komen-Announce-National-Partnership-to-Accelerate-Progress-Against-Breast-Cancer/default.aspx

0 · Reply

malaika1285 Aug. 28 at 1:30 PM

$NTRA $VOD $WDAY 💣 Big move loading? Core AI Holdings reports +56% Q2 top-line revenue growth. Eyes on this trend 👁️🚀

0 · Reply

WAJeff Aug. 27 at 7:55 PM

Only changes to top 50 gainers were $NTRA (47.9% ytd) rising to #22, $GH (65.59% ytd) rising to #37, and $HWM (29.63% ytd) falling to #30 because of FIFO. HWM was #19 last year, GH was #23 last year, and NTRA was just outside the top 30. Still like all of them, GH/NTRA have run hard recently and may need a break.

0 · Reply

Stocktwits52wHighs Aug. 27 at 2:31 PM

$NTRA printed a new 52-week high today

0 · Reply

Natera initiated with a Buy at Rothschild & Co Redburn

Sep 2, 2026, 12:04 PM EDT - 5 days ago

Why Moderna's Cancer Vaccine Matters to Investors

DHR HTEC ILMN MRK MRNA ROG TEM

2026-09-01T10:25:59.000Z - 7 days ago

Natera announces publication of new data in Blood Neoplasia on Signatera

Sep 1, 2026, 6:00 AM EDT - 7 days ago

New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

Aug 28, 2026, 11:03 AM EDT - 10 days ago

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

2026-08-27T10:10:46.000Z - 12 days ago

Natera and Angiex partner in tumor testing using Signatera

Aug 27, 2026, 6:00 AM EDT - 12 days ago

Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™

2026-08-17T10:16:19.000Z - 22 days ago

Natera to support new clinical trial assessing ctDNA dynamics with Latitude

2026-08-17T10:05:11.000Z - 22 days ago

Natera price target raised to $363.50 from $249 at Piper Sandler

2026-08-17T10:04:01.000Z - 22 days ago

Natera price target raised to $360 from $290 at Guggenheim

2026-08-17T09:25:20.000Z - 22 days ago

Natera price target raised to $350 from $305 at Stephens

2026-08-17T08:13:39.000Z - 22 days ago

Natera price target raised to $365 from $315 at Citi

Aug 12, 2026, 12:00 PM EDT - 26 days ago

Natera Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 12, 2026, 6:00 AM EDT - 27 days ago

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

2026-08-10T12:36:09.000Z - 4 weeks ago

Natera price target raised to $355 from $310 at Morgan Stanley

Aug 7, 2026, 5:10 PM EDT - 4 weeks ago

Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status

2026-08-07T13:15:52.000Z - 4 weeks ago

Natera price target raised to $340 from $325 at TD Cowen

2026-08-07T12:56:48.000Z - 4 weeks ago

Natera price target raised to $360 from $300 at Evercore ISI

2026-08-07T12:25:38.000Z - 4 weeks ago

Natera price target raised to $350 from $275 at RBC Capital

2026-08-07T12:02:04.000Z - 4 weeks ago

Natera price target lowered to $348 from $379 at Baird

2026-08-07T11:36:12.000Z - 4 weeks ago

Natera price target raised to $375 from $330 at Canaccord

2026-08-07T11:20:54.000Z - 4 weeks ago

Natera price target raised to $360 from $315 at JPMorgan

2026-08-07T11:10:39.000Z - 4 weeks ago

Natera price target raised to $284 from $220 at Wells Fargo

2026-08-07T11:00:52.000Z - 4 weeks ago

Natera price target raised to $315 from $300 at Citi

2026-08-07T10:55:33.000Z - 4 weeks ago

Natera price target raised to $320 from $290 at BTIG

2026-08-07T10:50:36.000Z - 4 weeks ago

Natera price target raised to $330 from $280 at Leerink

2026-08-07T10:11:43.000Z - 4 weeks ago

Natera price target raised to $340 from $260 at Barclays

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Natera Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Natera Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Natera Slides: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 4 weeks ago

Natera Quarterly report: Q2 2026

Aug 6, 2026, 4:05 PM EDT - 4 weeks ago

Natera Reports Second Quarter 2026 Financial Results

Aug 5, 2026, 6:00 AM EDT - 4 weeks ago

Natera Submits Signatera™ to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Jul 30, 2026, 8:00 AM EDT - 5 weeks ago

Natera to Report its Second Quarter Results on August 6, 2026

Jul 22, 2026, 6:00 AM EDT - 6 weeks ago

Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study

Jul 16, 2026, 6:35 PM EDT - 7 weeks ago

Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera™ Portfolio

Jul 9, 2026, 6:00 AM EDT - 2 months ago

Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers

Jul 6, 2026, 6:00 AM EDT - 2 months ago

Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer

Jun 29, 2026, 6:55 AM EDT - 2 months ago

Natera, Aveta partner on late-stage head and neck cancer trial

Jun 29, 2026, 6:00 AM EDT - 2 months ago

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer

Jun 25, 2026, 7:00 AM EDT - 2 months ago

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

ELDN

Jun 24, 2026, 5:00 AM EDT - 2 months ago

Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

Jun 23, 2026, 6:00 AM EDT - 2 months ago

NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

Jun 18, 2026, 6:00 AM EDT - 2 months ago

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

Jun 11, 2026, 2:30 PM EDT - 2 months ago

Natera Transcript: AGM 2026

Jun 8, 2026, 9:20 AM EDT - 3 months ago

Natera Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 8:00 AM EDT - 3 months ago

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Jun 3, 2026, 8:00 AM EDT - 3 months ago

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

$Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma$

May 29, 2026, 6:00 AM EDT - 3 months ago

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

May 28, 2026, 6:00 AM EDT - 3 months ago

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

May 26, 2026, 6:00 AM EDT - 3 months ago

Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology

May 21, 2026, 5:05 PM EDT - 3 months ago

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

May 21, 2026, 7:00 AM EDT - 3 months ago

Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World

May 20, 2026, 7:00 AM EDT - 3 months ago

EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled

May 15, 2026, 12:45 PM EDT - 3 months ago

Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

May 14, 2026, 5:30 AM EDT - 3 months ago

The Cancer Test That Wall Street Is Betting On

May 10, 2026, 2:30 PM EDT - 4 months ago

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

EW ISRG LLY NVO

May 7, 2026, 4:30 PM EDT - 4 months ago

Natera Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Natera Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Natera Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Natera Quarterly report: Q1 2026

May 7, 2026, 4:05 PM EDT - 4 months ago

Natera Reports First Quarter 2026 Financial Results

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Natera to Report its First Quarter Results on May 7, 2026

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Natera Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Natera Proxy statement: Proxy filing

Apr 22, 2026, 9:00 AM EDT - 4 months ago

Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

ALLO

Apr 9, 2026, 6:00 AM EDT - 5 months ago

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

Apr 7, 2026, 6:00 AM EDT - 5 months ago

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform

Mar 31, 2026, 6:00 AM EDT - 5 months ago

SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery

Mar 16, 2026, 6:00 AM EDT - 5 months ago

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

Mar 12, 2026, 8:00 AM EDT - 6 months ago

MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Natera Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 1:05 PM EST - 6 months ago

Natera Transcript: 47th Annual Raymond James Institutional Investor Conference

Feb 27, 2026, 10:05 AM EST - 6 months ago

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

Feb 26, 2026, 4:30 PM EST - 6 months ago

Natera Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

Natera Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

Natera Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

Natera Slides: Q4 2025

Feb 26, 2026, 4:05 PM EST - 6 months ago

Natera Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 24, 2026, 6:00 AM EST - 6 months ago

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

Feb 17, 2026, 9:00 AM EST - 6 months ago

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

Feb 6, 2026, 6:00 AM EST - 7 months ago

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Feb 2, 2026, 6:00 AM EST - 7 months ago

Natera Submits Signatera™ CDx PMA to FDA

Jan 28, 2026, 8:00 AM EST - 7 months ago

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

Jan 26, 2026, 6:00 AM EST - 7 months ago

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

Jan 21, 2026, 6:00 AM EST - 7 months ago

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

Jan 20, 2026, 6:00 AM EST - 7 months ago

Natera's Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

JUST_FACTSSS Sep. 3 at 10:39 PM

$NTRA SPRTS = 290.00 (50DMA)+272 +263 +251(100DMA) <--' BUY 🎯

0 · Reply

MaverikIT Sep. 1 at 6:16 PM

Jblack500 @WAJeff @cynicaloptimist @BustaCapital @IsabellaDC $IRTC $GH $NTRA PLSE ...

0 · Reply

peloswing Sep. 1 at 5:52 PM

Unusual Options Activity: $NTRA $1.6M+ of the $350 calls for 11/20 Also $63,000 of the $410 calls for Aug. 2027

0 · Reply

Agile_Mango_Penguin Sep. 1 at 11:56 AM

$NTRA AMP capital updated price target $500 in 2027

0 · Reply

S_Franconi Sep. 1 at 11:45 AM

0 · Reply

JFDI Aug. 30 at 7:42 PM

$NTRA druck sayzzzz dips r a ...

0 · Reply

S_Franconi Aug. 28 at 4:51 PM

0 · Reply

malaika1285 Aug. 28 at 1:30 PM

$NTRA $VOD $WDAY 💣 Big move loading? Core AI Holdings reports +56% Q2 top-line revenue growth. Eyes on this trend 👁️🚀

0 · Reply

WAJeff Aug. 27 at 7:55 PM

0 · Reply

Stocktwits52wHighs Aug. 27 at 2:31 PM

$NTRA printed a new 52-week high today

0 · Reply

WAJeff Aug. 26 at 2:08 PM

$NTRA $GH Great run for both

0 · Reply

WAJeff Aug. 25 at 10:10 PM

$NTRA $338.95 ath, relentless

0 · Reply

WAJeff Aug. 25 at 2:10 PM

$NTRA Some sold 334.98, 335.90 ath

0 · Reply

Stocktwits52wHighs Aug. 25 at 2:01 PM

$NTRA printed a new 52-week high today

0 · Reply

MaverikIT Aug. 21 at 7:26 PM

@Jblack500 @IsabellaDC @cynicaloptimist @BustaCapital @WAJeff @No_Face_character $TWST "Come on let's twist again, Like we did last summer! Yeaaah, let's twist again, Like we did last year! " $NTRA $TEM ... WGS HTFL

1 · Reply

Stocktwits52wHighs Aug. 20 at 6:31 PM

$NTRA printed a new 52-week high today

0 · Reply